Illumina Inc ILMN

Illumina, Inc. es un proveedor de soluciones basadas en secuenciación y arrays para análisis genético y genómico. La compañía opera a través de dos segmentos: Core Illumina y GRAIL. Los productos y servicios de Core Illumina sirven a clientes en los mercados de investigación, clínico y aplicado, y permiten la adopción de una variedad de soluciones genómicas. GRAIL es una empresa de salud centrada en la detección temprana de múltiples tipos de cáncer. Su portafolio de sistemas integrados de secuenciación y microarrays, consumibles y herramientas de análisis está diseñado para análisis genético. Los clientes utilizan sus plataformas para realizar secuenciación de genoma completo, de novo, exoma y ácido ribonucleico (ARN), y resecuenciación dirigida de regiones y genes específicos. La tecnología BeadArray de la compañía produce arrays que pueden realizar múltiples ensayos simultáneamente. Los clientes utilizan sus consumibles de genotipado basados en arrays para una variedad de análisis, incluyendo especies diversas, mutaciones relacionadas con enfermedades y características genéticas asociadas con el cáncer.

ILMN hizo una división de acciones (split) de 2:1 el 23 de septiembre de 2008: cada acción se convirtió en 2. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 5 oct

  Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR

  The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

  

• GlobeNewswire Inc. 1 oct

  Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight

  The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region.

  

• The Motley Fool 30 sept

  3 Reasons to Buy Grail (GRAL) Hand Over Fist in October

  Grail, spun off from Illumina in 2024, develops the Galleri blood test for early cancer detection. The company has grown revenue from $93M (2023) to $147M (2025) through cash-only sales and is expected to reach $181M in 2026. An FDA panel recently endorsed premarket approval with three affirmative votes, potentially supporting FDA approval by 2027. Despite trading at 21x 2028 sales, analysts believe the stock could be undervalued if FDA approval comes early and adoption accelerates.

  

• The Motley Fool 29 sept

  Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off?

  Illumina is developing an AI strategy centered on biological data from its sequencing technology. The company's initiatives, including the Billion Cell Atlas and expanded drugmaker partnerships, could create a new growth engine if it successfully converts its scientific advantages into recurring commercial revenue.

  

• Zacks Investment Research 29 sept

  REGN or ILMN: Which Is the Better Value Stock Right Now?

  A comparison of two Medical-Biomedical and Genetics stocks reveals that Regeneron (REGN) presents a better value opportunity than Illumina (ILMN) for value investors. REGN has a stronger Zacks Rank of #1 (Strong Buy) versus ILMN's #2 (Buy), along with significantly more attractive valuation metrics including a forward P/E of 14.16 versus ILMN's 50.77, and a PEG ratio of 1.23 versus 3.85.